Price Action Don’t Lie: Does EXACT Sciences Corporation Have Any Gas After Today’s Big Decline?

Price Action Don't Lie: Does EXACT Sciences Corporation Have Any Gas After Today's Big Decline?

The stock of EXACT Sciences Corporation (NASDAQ:EXAS) is a huge mover today! About 1.14 million shares traded hands. EXACT Sciences Corporation (NASDAQ:EXAS) has risen 210.82% since March 9, 2016 and is uptrending. It has outperformed by 203.41% the S&P500.
The move comes after 6 months negative chart setup for the $1.91B company. It was reported on Oct, 12 by We have $17.20 PT which if reached, will make NASDAQ:EXAS worth $133.70M less.

Analysts await EXACT Sciences Corporation (NASDAQ:EXAS) to report earnings on November, 3. They expect $-0.44 earnings per share, up 2.22% or $0.01 from last year’s $-0.45 per share. After $-0.46 actual earnings per share reported by EXACT Sciences Corporation for the previous quarter, Wall Street now forecasts -4.35% EPS growth.

EXACT Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

Out of 13 analysts covering EXACT Sciences (NASDAQ:EXAS), 5 rate it a “Buy”, 1 “Sell”, while 7 “Hold”. This means 38% are positive. EXACT Sciences has been the topic of 25 analyst reports since July 24, 2015 according to StockzIntelligence Inc. Canaccord Genuity maintained the stock with “Buy” rating in Wednesday, October 7 report. The firm earned “Buy” rating on Friday, July 24 by Lake Street. The firm has “Neutral” rating given on Tuesday, October 6 by Goldman Sachs. The rating was maintained by Roth Capital on Tuesday, October 6 with “Buy”. The firm earned “Buy” rating on Thursday, June 16 by Craig Hallum. As per Thursday, February 25, the company rating was downgraded by Roth Capital. The firm has “Sell” rating given on Friday, February 26 by Empire. The rating was maintained by Roth Capital with “Buy” on Friday, October 30. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by Jefferies on Wednesday, July 27. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by TH Capital on Friday, October 30.

According to Zacks Investment Research, “EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.”

Insitutional Activity: The institutional sentiment increased to 1.42 in Q2 2016. Its up 0.70, from 0.72 in 2016Q1. The ratio improved, as 18 funds sold all EXACT Sciences Corporation shares owned while 41 reduced positions. 30 funds bought stakes while 54 increased positions. They now own 87.89 million shares or 11.45% more from 78.86 million shares in 2016Q1.
Arrowpoint Asset Mgmt Limited Liability Corp last reported 0.51% of its portfolio in the stock. Friess Assoc Ltd Company reported 54,000 shares or 0.07% of all its holdings. The Virginia-based Redmond Asset Mngmt Limited Company has invested 0.52% in EXACT Sciences Corporation (NASDAQ:EXAS). Communications Tx has 0.12% invested in the company for 165,120 shares. Focused Wealth Management last reported 0% of its portfolio in the stock. Jane Street Gru Limited Company has 53,670 shares for 0% of their US portfolio. Price T Rowe Assoc Incorporated Md last reported 0% of its portfolio in the stock. Quantitative Management Lc holds 0.07% of its portfolio in EXACT Sciences Corporation (NASDAQ:EXAS) for 127,000 shares. Us Bank & Trust De reported 248,822 shares or 0.01% of all its holdings. California State Teachers Retirement Systems accumulated 0.01% or 203,042 shares. Shannon River Fund Limited Liability Company last reported 3.52% of its portfolio in the stock. D E Shaw And holds 0.1% or 4.57 million shares in its portfolio. Carl Domino Inc holds 25,000 shares or 0.29% of its portfolio. Moreover, Elk Creek Ltd Liability has 1.05% invested in EXACT Sciences Corporation (NASDAQ:EXAS) for 1.17 million shares. Ladenburg Thalmann Ser Inc last reported 0% of its portfolio in the stock.

Insider Transactions: Since July 25, 2016, the stock had 2 insider buys, and 3 sales for $97,947 net activity. On Monday, July 25 the insider ARORA MANEESH sold $109,060. Shares for $109,416 were sold by LIDGARD GRAHAM PETER on Monday, July 25. On Friday, September 30 the insider COWARD D SCOTT sold $30,584. 3,380 EXACT Sciences Corporation (NASDAQ:EXAS) shares with value of $60,613 were bought by Zanotti Katherine S. On Thursday, September 1 the insider Sterling Lionel bought $90,500.

Another recent and important EXACT Sciences Corporation (NASDAQ:EXAS) news was published by which published an article titled: “Exact Sciences Announces Inclusion of CologuardĀ® in HEDIS Quality Measures” on October 03, 2016.

EXAS Company Profile

Exact Sciences Corporation, incorporated on February 10, 1995, is a molecular diagnostics firm focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline. The Firm has developed a non invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The Company’s Cologuard test is a non invasive stool based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody based fecal immunochemical test (FIT). The United States Food and Drug Administration (FDA) approved Cologuard for use as sDNA non-invasive colorectal cancer screening test. Cologuard is available through healthcare providers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment